These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 15602726

  • 1. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
    Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, Sakaguchi H, Seki S, Shiomi S, Nishiguchi S.
    J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
    [Abstract] [Full Text] [Related]

  • 2. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J, Wang Z, Zhou B, Wang Y, Hou J.
    Antivir Ther; 2012 Feb; 17(1):71-9. PubMed ID: 22267471
    [Abstract] [Full Text] [Related]

  • 3. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R.
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [Abstract] [Full Text] [Related]

  • 4. [Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment].
    Chen JJ, Wang ZH, Ma SW, Chen YP, Peng J, Guo YB, Hou JL.
    Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):416-20. PubMed ID: 18578990
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
    Sayan M, Mutlu B, Erdoğan S, Meriç M, Willke A.
    Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P, Trabaud MA, Pradat P, Lebouché B, Chevallier M, Chevallier P, Zoulim F, Trepo C.
    Clin Infect Dis; 2007 Sep 01; 45(5):624-32. PubMed ID: 17682999
    [Abstract] [Full Text] [Related]

  • 11. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients.
    Gramenzi A, Loggi E, Micco L, Cursaro C, Fiorino S, Galli S, Gitto S, Galli C, Furlini G, Bernardi M, Andreone P.
    J Viral Hepat; 2011 Oct 01; 18(10):e468-74. PubMed ID: 21914065
    [Abstract] [Full Text] [Related]

  • 12. [Clinical evaluation of a novel HBsAg quantitative assay].
    Takagi K, Tanaka Y, Naganuma H, Hiramatsu K, Iida T, Takasaka Y, Mizokami M.
    Rinsho Byori; 2007 Jul 01; 55(7):619-25. PubMed ID: 17718057
    [Abstract] [Full Text] [Related]

  • 13. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF.
    Am J Gastroenterol; 2011 Oct 01; 106(10):1766-73. PubMed ID: 21826112
    [Abstract] [Full Text] [Related]

  • 14. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R.
    Liver Transpl; 2001 Feb 01; 7(2):113-7. PubMed ID: 11172394
    [Abstract] [Full Text] [Related]

  • 15. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B.
    Buti M, Sánchez F, Cotrina M, Jardi R, Rodríguez F, Esteban R, Guardia J.
    J Infect Dis; 2001 Apr 15; 183(8):1277-80. PubMed ID: 11262212
    [Abstract] [Full Text] [Related]

  • 16. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF.
    J Viral Hepat; 2007 Nov 15; 14(11):767-74. PubMed ID: 17927612
    [Abstract] [Full Text] [Related]

  • 17. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
    Yao G, Wang B, Cui Z, Yao J, Zeng M.
    Chin Med J (Engl); 1999 May 15; 112(5):387-91. PubMed ID: 11593504
    [Abstract] [Full Text] [Related]

  • 18. Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients.
    Lu L, Zhang HY, Yueng YH, Cheung KF, Luk JM, Wang FS, Lau GK.
    J Viral Hepat; 2009 Feb 15; 16(2):104-12. PubMed ID: 19175882
    [Abstract] [Full Text] [Related]

  • 19. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
    Kim JM, Choe BH, Chu MA, Cho SM.
    Korean J Hepatol; 2009 Jun 15; 15(2):168-78. PubMed ID: 19581769
    [Abstract] [Full Text] [Related]

  • 20. [Correlation of HBV DNA level and viral breakthrough during lamivudine therapy for chronic hepatitis B].
    Park HS, Lee DH, Heo J, Kim GH, Kang DH, Song GA, Cho M.
    Korean J Hepatol; 2006 Jun 15; 12(2):173-83. PubMed ID: 16804342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.